Diarrhea is a common side effect of GLP-1 medications (GLP-1 receptor agonists such as semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound). Across trials it affects roughly 12% to 30% of people depending on the drug, dose, and reason for treatment. The exact cause is not settled: these medicines change how the gut moves and secretes fluid, and shifts in lower-GI transit may be involved, though the evidence is still limited. It tends to show up when you start treatment or step up a dose, and for most people it is mild to moderate, with individual episodes lasting only a few days. Staying hydrated and easing your diet usually helps, and your prescriber decides whether an over-the-counter remedy fits. This is general information, not medical advice — talk to your prescriber about your own situation.
Why a GLP-1 can cause diarrhea
GLP-1 receptor agonists act throughout the digestive tract, and one effect is on how the lower gut moves and secretes fluid. A pharmacology review notes that changes in the rate of lower-GI transit may be responsible for diarrhea on these drugs, "although evidence is lacking" — so it is best understood as a plausible explanation rather than a proven one. Cleveland Clinic likewise describes the cause as not totally understood, and even raises the possibility that some loose stools are "overflow" around constipation rather than diarrhea in the usual sense.
What is clearer is the timing. Like the other gastrointestinal effects of this class, diarrhea is more likely when you start the medication or take an increased dose, which is the practical detail worth holding onto even while the mechanism stays uncertain.
How common is GLP-1 diarrhea?
How often diarrhea happens depends a lot on which medicine you take, at what dose, and whether it is prescribed for weight management or type 2 diabetes — so the honest answer is a range, anchored to specific populations rather than one headline number.
- Semaglutide (weight management): In the pooled STEP trials, diarrhea was reported by about 30% of people on semaglutide 2.4 mg versus about 16% on placebo.
- Tirzepatide (weight management): In the Zepbound trials, diarrhea occurred in roughly 19%, 21%, and 23% at the 5 mg, 10 mg, and 15 mg doses, versus about 8% on placebo.
- Tirzepatide (type 2 diabetes): Across the SURPASS diabetes trials, diarrhea ran roughly 12% to 22%.
Taken together, that puts the overall range at about 12% to 30%. When you compare your own experience against a figure, it is worth matching the population: the weight-management doses tend to sit at the higher end, and the diabetes data lower.
How long does GLP-1 diarrhea last?
For most people, GLP-1 diarrhea is an early, passing problem rather than a permanent one. Episodes cluster at the start of treatment and around dose increases, and the share of people affected tends to build to a peak around week 20 and then decline as the body adapts. The Zepbound labeling describes the same arc: gastrointestinal reactions occurred during dose escalation and decreased over time.
Individual bouts are usually short — in the semaglutide data, the median episode lasted about three days — and the majority of cases are mild to moderate. If yours is severe, lasts beyond a couple of days, or keeps coming back, that is worth raising with your prescriber rather than waiting it out. For the bigger picture across all side effects, see how long GLP-1 side effects last.
What actually helps
These are typical, prescriber-directed steps — not a prescription, and never a reason to change your dose on your own:
- Stay hydrated. Diarrhea loses fluid, so drinking enough to avoid dehydration is the first priority. Harvard Health advises to drink plenty of water and avoid dairy products and high-fiber foods until symptoms go away.
- Ease your diet for a while. Cutting back on dairy and high-fiber foods until things settle, then reintroducing them gradually, can make the gut more comfortable. See foods to eat and avoid.
- Let titration do the heavy lifting. Because diarrhea concentrates around dose increases, a gradual step-up is the single biggest lever — and it belongs to your prescriber. If side effects are rough, they may slow your escalation rather than push through it.
- Ask before reaching for an over-the-counter anti-diarrheal. Whether and when one of these products is appropriate is a prescriber's call, not a self-treatment default, especially alongside your other medicines — so check first rather than dosing on your own.
- Keep your regular follow-up. Staying in contact with your provider lets them adjust the plan if the diarrhea is not improving.
When to seek care
Most of the time, GLP-1 diarrhea is an early, mild-to-moderate nuisance that fades as your body adjusts. The point of knowing the red flags is so you can tell the difference quickly and get help when it matters.
Frequently asked questions
How common is diarrhea on a GLP-1? It depends on the drug and dose. Semaglutide 2.4 mg for weight management ran about 30% in trials versus about 16% on placebo; tirzepatide ran roughly 19% to 23% versus about 8% on placebo; in type 2 diabetes the figures are lower, around 12% to 22%. Match your situation to the right population rather than a single number.
How long does GLP-1 diarrhea last? Usually it is an early problem that eases over time. It flares most when you start or increase the dose, the share of people affected tends to peak around week 20 and then decline, and individual episodes are often short — a median of about three days in the semaglutide data. Persistent or worsening diarrhea is worth a call to your prescriber.
Can I take an over-the-counter anti-diarrheal with my GLP-1? That is a question for your prescriber, not a default. Whether and when one is appropriate depends on your situation and your other medicines, so ask first. In the meantime, focus on hydration and easing your diet, and do not change your dose to chase relief.
How we reviewed this: written from authoritative sources, including a peer-reviewed review of GLP-1 gastrointestinal effects, the FDA labeling for tirzepatide (Zepbound), Harvard Health on GLP-1 side effects and management, and Cleveland Clinic's overview of GLP-1 agonists. See our editorial and review policy and sourcing standards. Where evidence is limited — as with the exact mechanism behind GLP-1 diarrhea — we say so rather than overstating it.
Every clinical claim above is cited inline to a primary source. See how we review and our sourcing & fact-check standards.